Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials

Paolo A Ascierto

Melanoma, Cancer Immunotherapy, and Innovative Therapy, Istituto nazionale Tumori Fondazione “G Pascale”, Napoli, 80131, Italy

An example of international work and huge importance of a previously untreatable and lethal disease once spread. Now look at the options due to thoughtful science

Progression-free survival

The treatment of advanced melanoma has been revolutionised by the development of drug therapies targeting the mitogen-activated protein (MAP)-kinase pathway or immune checkpoints. Since 2011, at least eight drugs have been approved on the basis of improved overall survival in phase 3 randomised controlled trials.1–8 These eight drugs are the BRAF-inhibitors dabrafenib and vemurafenib, the MEK inhibitors trametinib and cobimetinib, the anti-CTLA4 antibody ipilimumab and the anti-programmed cell death protein 1 (anti-PD-1) antibodies pembrolizumab and nivolumab, and the oncolytic virus talimogen laherparepvec

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s